B2B Lead Generation for Biotech, Pharma, and Life Sciences

Biotech and pharma buyers hold vendor outreach to a higher factual standard than almost any other vertical. A clinical operations director will skim the first two sentences of an email to check for sloppy terminology. If the writer has confused a study endpoint with a secondary outcome, mixed up Phase 2 with Phase 2/3, or misapplied statistical language, the email goes straight to trash.

We run biotech campaigns with in-house scientific review on copy. Our writers are trained on clinical development language, regulatory frameworks, and study design terminology. The result is outbound that passes the credibility gate and produces actual conversations with clinical and regulatory leaders.

A pre-clinical biotech and a commercial-stage pharma do not buy the same things, in the same way, from the same people. Pre-clinical biotechs buy research reagents, lab services, and early CRO capacity. Commercial pharma buys market access, field-force enablement, and distribution optimization.

We build stage-specific target lists based on clinical trial registry data, recent funding, and pipeline signals. Each stage gets a different sequence. A Series B biotech with three programs in Phase 1 hears a completely different pitch from a top-20 pharma with commercial assets. This precision is how biotech outbound actually converts.